Table 2.
Theoreticala | MS | MS/MS | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Spot No | Protein Name | SwissProt entry | Biological functionb | MW (kDa) | pI | Peptide count | Protein score | Peptide count | Total ion score | Spot intensity ratioc | pd |
1 | Kininogen-1 | KNG1 | blood coagulation, source of bradykinin | 71912 | 6,34 | 5 | 184 | 0.110 | <0,0001 | ||
2 | Alpha-enolase | ENOA | glycolysis (step 9/10), cell growth, fibrinolysis | 47139 | 7,01 | 4 | 106 | 0.076 | <0,0001 | ||
3 | Glyceraldehyde-3-phosphate dehydrogenase | G3P | glycolysis (step 6/10), nuclear regulatory functions, apoptosis | 36030 | 8,57 | 2 | 57 | 0.018 | <0,0001 | ||
4 | Alpha-enolase | ENOA | 47139 | 7,01 | 6 | 57 | 5 | 257 | 0.140 | <0,0001 | |
5 | Glyceraldehyde-3-phosphate dehydrogenase | G3P | 36030 | 8,57 | 1 | 70 | 0.091 | <0,0001 | |||
6 | Vesicular integral-membrane protein VIP36 | LMAN2 | intracellular protein trafficking (Golgi to ER) | 40203 | 6,46 | 2 | 81 | 0.335 | <0,001 | ||
7 | Protein AMBP | AMBP | trypsin inhibitor | 38974 | 5,95 | 1 | 35 | 0.331 | <0,01 | ||
8 | Fibrinogen alpha chain | FIBA | blood coagulation | 94914 | 5,7 | 2 | 40 | 0.238 | <0,001 | ||
9 | Glutaminyl-peptide cyclotransferase | QPCT | N-terminal pyroglutamate formation | 40851 | 6,12 | 8 | 67 | 4 | 161 | 0.165 | <0,001 |
10 | Glutaminyl-peptide cyclotransferase | QPCT | 40851 | 6,12 | 3 | 99 | 0.190 | <0,0001 | |||
11 | Basement membrane-specific heparan sulphate proteoglycan core protein | PGBM | component of basement membrane, anti-angiogenesis | 468501 | 6,06 | 5 | 347 | 0. 364 | <0,001 | ||
12 | Non-secretory ribonuclease | RNAS2 | non-secretory ribonuclease | 18342 | 9,1 | 5 | 391 | 0.162 | <0,001 | ||
13 | Multimerin-2 | MMRN2 | endothelial surface protein, anti-angiogenesis | 104344 | 5,56 | 1 | 51 | 0.202 | <0,01 | ||
14 | Peptidoglycan recognition protein 1 | PGRP1 | pattern recognition, innate immunity | 21717 | 8,92 | 2 | 122 | 0.366 | <0,01 | ||
14 | Phosphatidylethanolamine-binding protein 1 | PEBP1 | serine protease inhibitor, Raf kinase inhibitor | 21044 | 7,01 | 1 | 58 | <0,01 | |||
15 | Inter-alpha-trypsin inhibitor heavy chain H4 | ITIH4 | immunomodulation (acute phase) | 103293 | 6,51 | 2 | 46 | 0.406 | <0,01 | ||
16 | Secreted and transmembrane protein 1 | SCTM1 | T-cell co-stimulatory ligand | 27022 | 7 | 2 | 93 | 0.219 | <0,01 | ||
17 | Secreted and transmembrane protein 1 | SCTM1 | 27022 | 7 | 1 | 37 | 0.156 | <0,001 | |||
18 | Serum albumin | ALBU | major plasma protein | 69321 | 5,92 | 2 | 82 | 1.9 | <0,001 | ||
19 | Serum albumin | ALBU | 69321 | 5,92 | 2 | 63 | 4.4 | <0,01 | |||
20 | Ig lambda-2 chain C region | LAC2 | immunoglobulin | 11287 | 6.92 | 2 | 188 | 3.1 | <0,0001 | ||
20 | Ig kappa chain C region | IGKC | immunoglobulin | 11602 | 5.58 | 1 | 44 | <0,05 | |||
21 | Zinc-alpha-2-glycoprotein | ZA2G | fatty acid binding | 34237 | 5,71 | 10 | 54 | 2 | 196 | 3.8 | <0,0001 |
22 | Serotransferrin | TRFE | iron binding, cell proliferation | 77000 | 6,81 | 23 | 119 | 3 | 193 | 2.8 | <0,01 |
23 | Ceruloplasmin | CERU | copper binding | 122128 | 5,44 | 7 | 495 | 1.2 | <0,0001 | ||
24 | Serum albumin | ALBU | 69321 | 5,92 | 4 | 150 | 3.9 | <0,001 | |||
25 | Serum albumin | ALBU | 69321 | 5,92 | 2 | 83 | 3.9 | <0,01 | |||
26 | Serum albumin | ALBU | 69321 | 5,92 | 2 | 113 | 5.0 | <0.01 | |||
27 | Mannan-binding lectin serine protease 2 | MASP2 | complement activation (lectin pathway) | 75685 | 5,47 | 7 | 430 | 4.2 | <0,001 | ||
28 | Serum albumin | ALBU | 69321 | 5,92 | 4 | 95 | 5.6 | <0,0001 | |||
29 | Serum albumin | ALBU | 69321 | 5,92 | 2 | 46 | 8.5 | <0,0001 | |||
30 | Alpha-1-acid glycoprotein 1 | A1AG1 | immunomodulation (acute phase) | 23497 | 4,93 | 2 | 82 | 4.1 | <0,001 | ||
31 | Serotransferrin | TRFE | 77000 | 6,81 | 22 | 111 | 4 | 248 | 11.6 | <0,0001 | |
32 | Serotransferrin | TRFE | 77000 | 6,81 | 23 | 147 | 8 | 268 | 3.8 | <0,0001 | |
33 | Serotransferrin | TRFE | 77000 | 6,81 | 26 | 151 | 5 | 396 | 5.5 | NS |
aTheoretical MW and pI were retrieved from SwissProt database and correspond to intact proteins, irrespective of post-translational modifications
bDescriptions of proteins’ biological functions were extracted from SwissProt database
cSpot intensity ratios are calculated from group averages and expressed relative to non-microalbuminuric group
dMedian spot volumes were compared between the two groups using Mann–Whitney rank sum test